BUSINESS

Quest Diagnostics Reports Strong Q1, Raises Guidance

PUBLISHED Apr 21, 2026, 8:02 AM ET

Read, Watch or Listen

Media Bias Meter

Sources: 4

Center 100%

Sources: 4

SECAUCUS, N.J. — Quest Diagnostics reported first-quarter 2026 results on April 21, 2026, announcing net income of about $251–$252 million, GAAP EPS of $2.24 and adjusted EPS of $2.50 on revenue near $2.9 billion. The company also updated full-year adjusted diluted EPS guidance to $10.63–$10.83 and net revenue guidance to $11.78–$11.90 billion. The results topped Zacks consensus estimates for both earnings and revenue on Tuesday, and management cited roughly 9% organic revenue growth in the quarter when raising guidance. In pre-market trading this week, Quest shares were reported up about 2.39 percent, and analysts and investors will monitor second-quarter trends and execution against the revised 2026 outlook.

By Michael Grant | JQJO News

Timeline of Events

March 31, 2026: End of Quest Diagnostics' first-quarter reporting period.
April 21, 2026: Quest issued Q1 financial results and updated full-year guidance.
April 21, 2026: Newswire and media outlets (PR Newswire, AP, RTT/dpa-AFX) distributed the results.
April 21, 2026: Zacks consensus comparison published; results reported to have topped estimates.
April 21, 2026: Pre-market trading showed Quest shares rising following the guidance update.

News Intelligence

Quest Diagnostics' strong Q1 results could impact your wallet. If you own shares, you're likely seeing a boost in your investment. If you're considering investing, this might be a company to watch. Check your portfolio or speak with your financial advisor.

Media Bias

Articles Published:: 4
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 4

Who Benefited

Shareholders and company management benefited from stronger-than-expected first-quarter results and raised 2026 guidance, which supported a near-term share price increase.

Who Impacted

Competing diagnostic labs and short-term market bears faced pressure from Quest Diagnostics’ stronger performance and upward revision to full-year guidance.

Media Bias

Articles Published:: 4
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 4
Distribution:: Left 0%, Center 100%, Right 0%

Who Benefited

Shareholders and company management benefited from stronger-than-expected first-quarter results and raised 2026 guidance, which supported a near-term share price increase.

Who Impacted

Competing diagnostic labs and short-term market bears faced pressure from Quest Diagnostics’ stronger performance and upward revision to full-year guidance.